Brief: Pharmather Applies For FDA Orphan Drug Designation For Ketamine To Treat Rare Neurological Disorder Status Epilepticus
24/11/2021 12:31
Nov 24 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER APPLIES FOR FDA ORPHAN DRUG DESIGNATION FOR
KETAMINE
TO TREAT RARE NEUROLOGICAL DISORDER STATUS EPILEPTICUS
Source text for Eikon: ID:nGNX7B1ykr
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application